{"transactions":[{"id":685677,"issuer":{"id":7018,"kind":"organization","name":"MDxHealth SA"},"owners":[{"id":22922,"kind":"person","name":"MVM Partners, LLC","position":1,"cik":"0001947083","reported_name":"MVM Partners, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":22923,"kind":"person","name":"Bednarski Eric","position":2,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-17T20:05:06.000Z","date":"2026-08-13","kind":"purchase","planned":false,"acquired":true,"shares":2202643,"price":0.454,"value":999999.922,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Ordinary shares, no par value, of MDxHealth SA (the \"Issuer\") purchased pursuant to securities purchase agreements by and between the Issuer and certain private investment vehicles managed by MVM Partners, LLC (the \"Funds\"), each dated as of August 11, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are directly owned by the Funds. The securities may also be deemed beneficially owned by MVM Partners, LLC (\"MVM\") as the investment manager of the Funds and by Eric Bednarski as Managing Member of MVM. Each of Mr. Bednarski and MVM disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interests therein, if any, and this Form 4 shall not be deemed an admission that either Mr. Bednarski or MVM is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6903100,"source":{"system":"sec-edgar","filing":"0001193125-26-354021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872529/000119312526354021/ownership.xml","form_type":"4"}},{"id":1138963,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:23:55.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":24.45,"expiration_date":"2031-12-10","underlying":"Common Stock","underlying_shares":1925},"source":{"system":"sec-edgar","filing":"0001104659-25-051343","document":"tm2515648-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051343/tm2515648-7_4seq1.xml","form_type":"4"}},{"id":1138962,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:23:55.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2133,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":29.25,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":2133},"source":{"system":"sec-edgar","filing":"0001104659-25-051343","document":"tm2515648-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051343/tm2515648-7_4seq1.xml","form_type":"4"}},{"id":1138961,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:23:55.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3566,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":17.7,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":3566},"source":{"system":"sec-edgar","filing":"0001104659-25-051343","document":"tm2515648-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051343/tm2515648-7_4seq1.xml","form_type":"4"}},{"id":1138960,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T09:23:55.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":15.6,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001104659-25-051343","document":"tm2515648-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000110465925051343/tm2515648-7_4seq1.xml","form_type":"4"}},{"id":1486705,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T16:22:39.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 6, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":75000,"derivative":{"exercise_price":1.04,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001494650-24-000081","document":"wk-form4_1717791748.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465024000081/wk-form4_1717791748.xml","form_type":"4"}},{"id":1860460,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T14:09:52.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":53500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 8, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":53500,"derivative":{"exercise_price":1.18,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":53500},"source":{"system":"sec-edgar","filing":"0001494650-23-000063","document":"wk-form4_1686334182.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465023000063/wk-form4_1686334182.xml","form_type":"4"}},{"id":2237737,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T10:17:04.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier of (i) June 8, 2023 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2023 annual meeting of stockholders, subject to continued service with the Issuer."}],"balance_after":32000,"derivative":{"exercise_price":1.95,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001494650-22-000058","document":"wf-form4_165478420693989.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465022000058/wf-form4_165478420693989.xml","form_type":"4"}},{"id":2475462,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":22923,"kind":"person","name":"Bednarski Eric","position":1,"cik":"0001897581","reported_name":"Bednarski Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-13T15:58:03.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":28879,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable over a three-year period commencing on December 10, 2021. Thirty-three percent (33%) of the option vests and becomes exercisable on December 10, 2022, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining two years of the three-year period, subject to continued service with the Issuer."}],"balance_after":28879,"derivative":{"exercise_price":1.63,"expiration_date":"2031-12-10","underlying":"Common Stock","underlying_shares":28879},"source":{"system":"sec-edgar","filing":"0001494650-21-000147","document":"wf-form4_163942906877243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1494650/000149465021000147/wf-form4_163942906877243.xml","form_type":"4"}}]}